GOSS [NASD]
Gossamer Bio, Inc.
Index- P/E- EPS (ttm)-3.11 Insider Own1.50% Shs Outstand75.89M Perf Week14.75%
Market Cap678.68M Forward P/E- EPS next Y-2.42 Insider Trans-5.69% Shs Float68.96M Perf Month26.29%
Income-234.10M PEG- EPS next Q-0.68 Inst Own79.40% Short Float17.53% Perf Quarter-2.33%
Sales- P/S- EPS this Y12.00% Inst Trans1.79% Short Ratio13.76 Perf Half Y-22.28%
Book/sh0.40 P/B21.97 EPS next Y14.60% ROA-64.20% Target Price15.70 Perf Year6.67%
Cash/sh3.52 P/C2.50 EPS next 5Y5.20% ROE-172.80% 52W Range5.64 - 14.30 Perf YTD-22.28%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-38.53% Beta0.88
Dividend %- Quick Ratio8.10 Sales past 5Y- Gross Margin- 52W Low55.85% ATR0.53
Employees185 Current Ratio8.10 Sales Q/Q- Oper. Margin- RSI (14)67.89 Volatility7.35% 7.63%
OptionableYes Debt/Eq7.42 EPS Q/Q2.10% Profit Margin- Rel Volume0.93 Prev Close8.36
ShortableYes LT Debt/Eq7.42 EarningsMay 10 AMC Payout- Avg Volume878.63K Price8.79
Recom1.80 SMA2023.42% SMA5018.71% SMA200-11.11% Volume805,388 Change5.14%
Apr-18-22Initiated Raymond James Outperform $19
Apr-06-22Initiated UBS Buy $19
Jan-10-22Upgrade SMBC Nikko Neutral → Outperform $24
Nov-09-21Resumed Cantor Fitzgerald Overweight $20
Sep-21-21Resumed Piper Sandler Overweight $26
Jun-29-20Initiated H.C. Wainwright Buy $31
Apr-22-20Initiated Piper Sandler Overweight $30
Feb-27-20Initiated Barclays Overweight $21
Dec-03-19Resumed BofA/Merrill Buy
Oct-30-19Initiated Berenberg Buy $31
Mar-05-19Initiated SVB Leerink Outperform $30
Mar-05-19Initiated Evercore ISI Outperform $30
Mar-05-19Initiated BofA/Merrill Buy $30
Mar-05-19Initiated Barclays Overweight $27
Jun-09-22 08:30AM  
May-26-22 09:55AM  
May-23-22 09:55AM  
May-10-22 04:01PM  
May-06-22 12:20PM  
Apr-25-22 07:29AM  
Mar-03-22 04:01PM  
Feb-28-22 07:01AM  
Jan-02-22 08:47AM  
Nov-08-21 04:01PM  
Nov-02-21 04:01PM  
Oct-11-21 08:36AM  
Oct-07-21 04:01PM  
Oct-03-21 10:45AM  
Sep-21-21 08:31AM  
Aug-09-21 04:01PM  
Aug-02-21 04:01PM  
Jul-21-21 05:16AM  
Jul-17-21 05:47AM  
Jul-07-21 07:01AM  
Jun-21-21 04:01PM  
Jun-14-21 04:01PM  
May-06-21 07:31AM  
Apr-20-21 07:50AM  
Apr-16-21 07:55AM  
Feb-25-21 07:31AM  
Feb-19-21 08:01AM  
Feb-04-21 07:05AM  
Jan-18-21 03:05AM  
Dec-19-20 03:54PM  
Dec-11-20 05:00PM  
Dec-07-20 07:03AM  
Nov-16-20 07:01AM  
Nov-10-20 04:01PM  
02:30PM  
08:00AM  
Nov-06-20 07:07AM  
07:03AM  
Oct-13-20 03:02PM  
07:04AM  
Oct-12-20 08:07AM  
Oct-09-20 08:01AM  
Sep-30-20 08:38AM  
Sep-10-20 07:07AM  
Sep-07-20 11:00AM  
Sep-01-20 04:30PM  
Aug-11-20 04:01PM  
Aug-05-20 08:31AM  
Jul-22-20 12:55PM  
08:12AM  
Jul-03-20 06:27PM  
Jun-08-20 09:00AM  
Jun-02-20 04:25PM  
04:00PM  
03:19PM  
01:57PM  
12:54PM  
12:30PM  
11:40AM  
11:00AM  
10:01AM  
09:21AM  
06:20AM  
Jun-01-20 11:45PM  
06:10PM  
05:25PM  
12:00PM  
11:07AM  
10:00AM  
10:00AM  
07:35AM  
06:20AM  
May-31-20 10:50PM  
12:53PM  
08:30AM  
May-30-20 03:39PM  
03:30PM  
May-29-20 03:40PM  
02:40PM  
01:45PM  
12:50PM  
11:33AM  
10:32AM  
08:07AM  
May-28-20 09:20PM  
08:40PM  
02:55PM  
12:00PM  
11:30AM  
11:02AM  
10:30AM  
06:30AM  
May-27-20 11:25PM  
06:20PM  
04:30PM  
01:40PM  
01:00PM  
11:26AM  
10:22AM  
08:48AM  
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Carter LauraChief Scientific OfficerJul 01Sale8.258,80872,64880,234Jul 05 04:39 PM
Aranda RichardChief Medical OfficerJun 22Sale6.881,77812,233209,897Jun 23 06:47 PM
Carter LauraChief Scientific OfficerMay 04Sale7.201,2629,08689,042May 05 06:14 PM
Christian WaageEVP, Tech Ops and AdminMar 23Sale8.9110,72295,587579,008Mar 24 04:57 PM
Hasnain FaheemPresident & CEOMar 23Sale8.9119,035169,697143,465Mar 24 04:55 PM
Giraudo BryanCOO/CFOMar 23Sale8.9110,72295,58799,167Mar 24 04:53 PM
Carter LauraChief Scientific OfficerMar 16Sale8.285,00241,40790,304Mar 17 05:03 PM
Peterson CarynEVP, Regulatory AffairsMar 16Sale8.286,27951,97866,172Mar 17 05:00 PM
Aranda RichardChief Medical OfficerMar 16Sale8.286,27851,976211,675Mar 17 04:58 PM
Peterson CarynEVP, Regulatory AffairsOct 25Sale12.252,37729,11872,451Oct 26 05:08 PM
Carter LauraChief Scientific OfficerOct 25Sale12.252,37729,11895,306Oct 26 05:01 PM
Aranda RichardChief Medical OfficerOct 25Sale12.252,37729,118217,432Oct 26 04:58 PM